What is the current best practice for managing moderate alopecia areata with concomitant facial involvement in a 27‑year‑old man, disease duration six months, and a Severity of Alopecia Tool (SALT) score of 15?

Management of Moderate Alopecia Areata (SALT 15)

For this 27-year-old man with moderate alopecia areata (SALT score 15) affecting scalp and beard for 6 months, intralesional triamcinolone acetonide injections represent the most appropriate first-line treatment, with monthly injections of 5-10 mg/mL administered to affected patches on both scalp and chin.

Treatment Rationale

Why Intralesional Corticosteroids Are Optimal Here

This patient's presentation falls into an ideal treatment window:

• SALT score of 15 indicates moderate disease (15% scalp involvement) - below the threshold for systemic therapy (typically SALT ≥20-50) 1
• 6-month duration suggests this is not self-limiting early disease that might spontaneously resolve
• Facial involvement (beard) makes this particularly suitable for intralesional therapy, which is specifically noted as "most suitable for treating patchy hair loss of limited extent and for cosmetically sensitive sites" 2

The evidence supporting intralesional corticosteroids shows:

• 62% achieved full regrowth with monthly triamcinolone acetonide injections 2
• Response was better in patients with fewer than five patches < 3 cm diameter - matching this patient's moderate presentation 2
• Effects lasted approximately 9 months 2

Specific Treatment Protocol

Intralesional Injection Technique

Medication: Triamcinolone acetonide 5-10 mg/mL (or hydrocortisone acetate 25 mg/mL as alternative) 2

Technique:

• Inject just beneath the dermis in the upper subcutis
• Use 0.05-0.1 mL per injection site
• Each injection produces approximately 0.5 cm diameter tuft of hair growth
• Space injections accordingly to cover affected areas
• Frequency: Monthly injections 2

For both scalp and chin involvement: Treat all affected patches at each session

Alternative Delivery Method

A needleless device (e.g., Dermajet) can be used if patient discomfort is limiting, showing 62% regrowth at 12 weeks with three injections 2

Adjunctive Therapy Considerations

Add Topical Minoxidil

While not addressing the autoimmune process, topical minoxidil (5%) can be used adjunctively to potentially enhance regrowth 3. This is low-risk and may provide additive benefit.

Potent Topical Corticosteroids - Limited Role

Clobetasol propionate 0.05% foam showed modest benefit (7 of 34 sites with ≥50% regrowth vs 1 of 34 with vehicle) 2, but this is less effective than intralesional therapy and better reserved for patients who refuse injections. Common pitfall: Folliculitis is a frequent side effect 2.

What NOT to Do at This Stage

Observation Alone Is Inappropriate

While spontaneous remission occurs in up to 80% of patients with limited patchy hair loss of short duration (<1 year) 2, this patient is already at 6 months with moderate involvement. The guideline specifically states "regrowth cannot be expected within 3 months of development of any individual patch" 2 - this patient is well past that window.

Systemic Therapy Is Premature

• JAK inhibitors (baricitinib, ritlecitinib, deuruxolitinib) are FDA/EMA-approved for severe AA (SALT ≥50) 3, 4, 1
• This patient's SALT score of 15 is well below this threshold
• Systemic immunosuppressants (methotrexate, cyclosporine, azathioprine) are typically reserved for SALT ≥20 1

Contact Immunotherapy (DPCP/SADBE) - Second-Line

While contact immunotherapy with diphenylcyclopropenone (DPCP) is effective, it requires:

• Initial sensitization with 2% solution
• Weekly applications with concentration titration
• Light protection for 24 hours post-application
• Risk of severe dermatitis, lymphadenopathy, and pigmentary changes 2

This complexity makes it more appropriate as second-line therapy if intralesional corticosteroids fail.

Monitoring and Follow-Up

Expected Timeline

• No response expected before 3 months from start of treatment 2
• Reassess at 3-4 months of monthly injections
• If achieving regrowth, continue until complete or near-complete resolution

If Treatment Fails After 4-6 Months

Escalation options in order:

1. Contact immunotherapy with DPCP - most evidence-based second-line option 2
2. Systemic corticosteroids (short-term pulse therapy) - if rapid progression occurs
3. JAK inhibitors - only if disease progresses to SALT ≥50 or meets severe criteria 3, 4, 1

Critical Caveats

Patient Counseling Points

• Relapse is common during or after initially successful treatment - warn patient upfront 2
• Treatment induces hair growth but does not alter long-term disease course 2
• Main limitation is patient discomfort from multiple injections 2
• Effects last approximately 9 months, may require maintenance 2

Psychological Considerations

Given the facial involvement in a young man, assess for depression and anxiety - these comorbidities significantly impact disease burden beyond just hair loss extent 5. Consider referral for psychological support if needed.